Alzamend Neuro rises on completion of Alzheimer's drug study

Alzamend Neuro

22/03/2023 14:01

** Shares of drug developer Alzamend Neuro Inc  ALZN.O  rise
7.3% to $0.45 
    ** Co says it has completed clinical portion of a mid-stage
study for its experimental drug to treat dementia related to
Alzheimer’s disease   
    ** The study evaluates the safety and tolerability of the
drug candidate, AL001, under multiple-dose conditions -ALZN 
    ** Co expects to report study results in June 
    ** AL001 is a lithium-based oral drug candidate to treat
patients with dementia related to mild, moderate, and severe
cognitive impairment associated with Alzheimer’s -ALZN
    ** Including session's moves, stock down ~65% in the past 12
months

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))